TransPharma Medical Expands Board of Directors with Appointment of Industry
Veteran Larry Ellberger
LOD, ISRAEL, March 12, 2007 - TransPharma Medical Ltd., a specialty
pharmaceutical company focused on the development and commercialization of drug
products utilizing a proprietary active transdermal drug delivery technology,
announced today the appointment of Larry Ellberger to the Company’s Board of
Directors.
“We are pleased to welcome such an experienced and accomplished industry
veteran to our Board. Larry brings with him over 30 years of experience in the
life science and drug delivery industries. His broad strategic planning and
corporate development expertise and high level relationships within the
pharmaceutical industry will serve TransPharma well,” said Dr. Daphna Heffetz,
Chief Executive Officer of TransPharma Medical Ltd. “We look forward to his
counsel as TransPharma achieves important milestones this year, entering
clinical trials for both our jointly developed hGH product with Teva and our
in-house development of hPTH (1-34). Our ability to recruit someone of Larry’s
stature to our team is a strong endorsement of the TransPharma business model
and value proposition.”
Mr. Ellberger is a Founder and Principal of HVA, Inc. a consulting firm
specializing in business development, product acquisition and licensing, and
mergers and acquisitions for pharmaceutical, biotechnology, drug delivery, and
medical device companies. He also is a member of the Board of Directors at Omrix
Biopharmaceuticals, Inc., a NASDAQ-listed commercial-stage biopharmaceutical
company that develops and markets biosurgical and passive immunotherapy
products. In addition, Mr. Ellberger is a Director at Avant Immunotherapeutics,
a NASDAQ-listed vaccine biotechnology company.
Most recently, Mr. Ellberger held the position of Interim CEO of PDI, Inc., a
sales and marketing service provider for pharmaceutical and biotech companies.
Prior to that, he was Senior Vice President of Corporate Development and a
member of the Board of Directors at PowderJect, a publicly-traded drug delivery
company, which became one of the first profitable biotechnology companies in
Europe following its IPO in 1997. Previously, Mr. Ellberger held several senior
positions during his 20 year tenure at American Cyanamid Company, a leading life
science company. He was also CFO and interim CEO at W.R. Grace & Co.
“I am delighted to join the board of TransPharma and look forward to
contributing to the growth of its business. The combination of TransPharma’s
unique transdermal drug delivery technology, together with its exceptional
leadership team, offers its partners – current and future – significant added
value in the development of innovative drug products,” commented Mr. Ellberger.
About TransPharma Medical
Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical
company focused on the development and commercialization of drug products
utilizing a proprietary active transdermal drug delivery technology. Providing
an easy-to-use, cost-effective, at-home solution, TransPharma’s ViaDerm drug
delivery system enables the delivery of a wide variety of product candidates,
including hydrophilic small molecules, peptides and proteins. TransPharma aims
to develop multiple drug products through strategic partnerships with leading
pharmaceutical companies and through independent product development. For more
information, visit the Company's website at www.transpharma-medical.com.
Company Contact:
Naomi Rabbie
Marketing Manager
+972-8-915-2201 x251
naomir@transpharma.co.il
|
